TFS HealthScience Standardizes on Veeva Vault Clinical Operations Suite to Accelerate Clinical Development
Veeva Systems (NYSE: VEEV) today announced that TFS HealthScience selected Veeva Vault Clinical Operations Suite for end-to-end study management on a single cloud platform. The global CRO is taking action to further modernize study operations, adopting the entire suite for greater efficiency and speed in trials. Now TFS HealthScience will offer its biopharma customers industry-leading technologies and services to run more cost-efficient and compliant studies.
"Veeva Vault Clinical Operations Suite gives us a foundation for further growth as we expand our service offerings globally," said Dr. Bassem Saleh, CEO, TFS HealthScience. "Bringing together study operations streamlines processes, enabling us to maximize value for sponsors and accelerate the delivery of treatments to patients."
TFS HealthScience provides customers with strategically tailored solutions focused on driving excellence and innovation to reduce complexity in trials. Building on its success with Veeva Vault eTMF to maintain inspection readiness, the company will use Veeva Vault Study Startup to get studies up and running quickly, Veeva Vault CTMS to keep studies on track, and Veeva Vault Payments to simplify payments to global partner sites. With a connected, agile clinical landscape, TFS HealthScience will centralize governance and study oversight to share insights with sponsors easily.
"With Veeva Vault, we now have complete visibility into study progress and deviations to make better, more informed decisions and ensure studies meet their objectives," said Young Shon, CIO, TFS HealthScience. "Our partnership with Veeva is instrumental to TFS's digital transformation program and our strategic push towards paperless and patient-centric approaches."
"TFS HealthScience is transforming clinical operations to work more efficiently and better serve sponsors," said Pinar Benet, senior director strategy, Vault Clinical Operations at Veeva Systems. "We're excited to continue this journey together towards unified and connected trials to accelerate clinical research."
Vault Clinical Operations Suite enables sponsors and CROs to seamlessly share information and documents across CTMS, eTMF, study start-up, and payments for better collaboration and increased efficiency throughout the study lifecycle.
The Veeva Unified Clinical Operations Survey: Annual CRO Report shows that CROs like TFS HealthScience are moving to streamline trial execution by embracing new digital strategies and technologies that eliminate data silos and manual processes. Learn how CROs are modernizing clinical operations to speed trials in the full report, available online at veeva.com/CROReport.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
About TFS HealthScience
TFS HealthScience is a global contract research organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 700 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through three strong business models: clinical development services (CDS), which provides full-service support at all stages of the clinical development process, strategic resourcing solutions (SRS), which offers expert insourcing and targeted recruitment services, and functional services (FSP), to provide customers with strategic workforce management solutions. For more information, visit www.tfscro.com
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 975 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended October 31, 2020. This is available on the company's website at veeva.com under the Investors section and on the SEC's website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005312/en/
Contact information
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
Sylwia Domagalska
TFS HealthScience
+48 787 913 074
sylwia.domagalska@tfscro.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AWS and HUMAIN Expand Partnership with NVIDIA AI Infrastructure and AWS AI Chip Deal to Drive Global AI Innovation19.11.2025 20:38:00 EET | Press release
Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and HUMAIN, a Public Investment Fund (PIF) company delivering global full-stack AI solutions, announced today at the U.S.-Saudi Investment Forum their plans to provide, deploy and manage up to 150,000 AI accelerators in a data center facility known as an “AI Zone” in Riyadh. As part of the expanded partnership, AWS will become HUMAIN’s preferred AI partner globally, and the two companies will collaborate to bring AI compute and services from Saudi Arabia to customers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119637708/en/ Tanuja Randery, Managing Director, Europe, Middle East & Africa, AWS and Tareq Amin, CEO of HUMAIN The first-of-a-kind AI Zone in Saudi Arabia will support cutting-edge AI training and inference workloads with access to the latest NVIDIA GB300 AI infrastructure and AWS’s Trainium AI chips. The infrastructure will
Luma AI Raises $900 Million Series C Led by HUMAIN And Partners on 2 Gigawatt AI Supercluster in Saudi Arabia19.11.2025 19:15:00 EET | Press release
Luma AI, the frontier artificial intelligence company building multimodal AGI, today announced it has raised $900 million in Series C funding, led by HUMAIN, a PIF company delivering global full-stack AI solutions, with significant participation from AMD Ventures, and existing investors Andreessen Horowitz, Amplify Partners, and Matrix Partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119678010/en/ (L–R) Amit Jain, CEO of Luma AI, and Tareq Amin, CEO of HUMAIN, at the U.S.–Saudi Investment Forum in Washington, D.C., where Luma AI announced its $900 million Series C and partnership on Project Halo - a 2-gigawatt AI supercluster in Saudi Arabia that will power next-generation World Models and accelerate the path toward Multimodal AGI. This Series C is a milestone in the company’s mission to build multimodal general intelligence: AI that can generate, understand, and operate in the physical world. To train and deploy
Synthio Labs Raises $5 Million to Build the Voice AI Operating System for Life Sciences Customer Engagement19.11.2025 17:00:00 EET | Press release
Synthio Labs, a clinical-grade voice AI company transforming how life sciences organisations engage clinicians and patients, today announced that it has raised $5 million in seed funding. The round was led by Elevation Capital with participation from 1984 Ventures, Peak XV Partners, Y Combinator, and several strategic angels from the global healthcare and AI ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119509940/en/ Rajashekar Vasantha (left), Supreet Deshpande (center), and Sahitya Sridhar (right), the founding team behind Synthio Labs’ voice-powered AI platform for pharma “We believe Synthio Labs is defining the next major Customer Engagement infrastructure for Life Sciences. Their Clinical-grade Voice AI platform unifies how pharma communicates - giving field teams a powerful voice companion, and giving physicians and patients instant, trusted, compliant answers 24/7. Pharma’s global Commercial and GTM foo
Torq Crushes EMEA Estimates With Record-Breaking Q3, Hitting 185% of Quarterly Target19.11.2025 16:00:00 EET | Press release
Torq, the autonomous security operations leader, today announced it has exceeded Q3 EMEA revenue estimates, achieving 185% of its quarterly target. Torq is now firmly established as EMEA’s autonomous security operations platform of choice as enterprise goliaths continue joining its customer ranks, including Virgin Atlantic, Kyocera, Siemens, and Zara. Torq’s EMEA headcount grew 400% across 2025 to accommodate the exponentially increasing demand. “As worldwide momentum accelerates, Torq is doubling down on its EMEA investment by expanding operations, growing regional leadership, and strengthening our on-the-ground presence to fuel our next stage of growth,” said Ofer Smadari, CEO and co-founder, Torq. “Torq is now trusted by many of the world’s largest brands inside some of the most complex and sophisticated security operations centers. With new expansion into Germany, Hungary, Poland, Slovenia, and Switzerland, we are continuing to scale our footprint across the region. EMEA’s most suc
Xsolla Releases “The Xsolla Report: State of Play Q3 2025 Edition, Vol. 8,” Delivering Clear, Data-Led Insights for Game Developers19.11.2025 16:00:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their products, today announces the release of The Xsolla Report: State of Play Q3 2025 Edition, Vol. 8, a comprehensive analysis of market forces shaping the games industry. The report synthesizes the latest data and expert perspectives to help developers and publishers plan for sustainable growth across platforms and regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119397781/en/ Graphic: Xsolla As developers navigate new distribution models and evolving monetization approaches, the Q3 2025 edition offers a practical perspective on where the market is heading. The global player base is projected to reach 3.6 billion by year-end, with revenue on track to reach $188.8 billion—driven by steady momentum, including console hardware refreshes, PC gains in Asia, and ongoing strength in mobile. Key highlights from the Q3 2025 edi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom